The drugs in question, called GLP-1 medicines, help spur insulin production after meals. Nine are approved in Europe and seven in the U.S., including include Merck’s Januvia and Janumet, Novo Nordisk’s Victoza and Bristol-Myers Squibb’s Byetta and Bydureon.

Read more